Ozempic drugmaker selects BE&K for US factory expansion
11 July 2024
Announced last month, Novo Nordisk – the Danish drugmaker that produces Ozempic and Wegovy, diabetes and weight-loss drugs – is investing more than US$4 billion to build another manufacturing facility in Clayton, North Carolina, US, and design-build company BE&K will be doing the work.
The construction site for drumaker Novo Nordisk’s expanded facility in North Caronlia, US. (Image: BE&K)
BE&K said the partnership involves managing a ‘multi-product facility’ adjacent to Novo Nordisk’s existing North Carolina operations. The new manufacturing campus is to be four-times the size of the original Clayton site.
Novo Nordisk confirmed the site will fill injection pens for popular treatments Wegovy and Ozempic.
The company said work will “enhance” the manufacturing capabilities by adding 1.4 million sq ft (130,064m2) to the footprint across “ten or more buildings” including multi-building combinations.
A value for the contract was not released.
“BE&K will directly perform a significant portion of the work as Construction Manager and will serve as the Agency Construction Manager for the remainder of the work, providing oversight for the development of the facility that will span approximately 56 acres [27 hectares],” said the company.
Construction, which is already underway, is expected to finalise between 2027 and 2029.
“BE&K has dedicated over two years of detailed preparation for this endeavour, providing estimates, schedules, and procurement strategies, and has begun construction,” confirmed the company.
